Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by MaxCyte, Inc

< Previous 1 2 Next >
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Signs Platform License Agreement with Adicet Bio
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Announces Retirement of Board Member Art Mandell
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Participate in Two Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Appoints Cynthia Collins to its Board of Directors
From MaxCyte, Inc
Via GlobeNewswire
Tickers CERT DMTKQ MXCT PSTX
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.